Lexaria Bioscience (LEXX) Net Income towards Common Stockholders (2014 - 2026)

Lexaria Bioscience has disclosed Net Income towards Common Stockholders across 13 years of filings, most recently posting $1.4 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $1.4 million, down 48.15% year-over-year; the trailing twelve-month figure through Feb 2026 was $9.5 million (up 1.06% YoY), and the FY2025 annual result was $11.9 million, up 105.17% from the prior year.
• Net Income towards Common Stockholders came in at $1.4 million for Q1 2026 at Lexaria Bioscience, down from $1.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $3.8 million in Q2 2025 to a low of -$2.4 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is $1.6 million (2025), against an average of $1.5 million.
• Across the five-year window, Net Income towards Common Stockholders surged 452.82% in 2022 and sank 53.85% in 2024, its largest moves.
• Lexaria Bioscience's Net Income towards Common Stockholders stood at $1.8 million in 2022, then plunged by 33.33% to $1.2 million in 2023, then jumped by 125.0% to $2.7 million in 2024, then plunged by 40.74% to $1.6 million in 2025, then declined by 12.5% to $1.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.